A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Study Details
Study Description
Brief Summary
This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab as monotherapy and in combination with zimberelimab in participants with advanced solid malignancies. In this dose escalation study, participants will receive domvanalimab administered intravenously as monotherapy or in combination with zimberelimab. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for study drug discontinuation occurs.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Domvanalimab Monotherapy Varying Doses of domvanalimab Monotherapy |
Drug: Domvanalimab
Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Other Names:
|
| Experimental: Domvanalimab + zimberelimab Q2W Combination Therapy Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab |
Drug: Domvanalimab
Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Other Names:
Drug: Zimberelimab
Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Other Names:
|
| Experimental: Domvanalimab + zimberelimab Q3W Combination Therapy Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab |
Drug: Domvanalimab
Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Other Names:
Drug: Zimberelimab
Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Other Names:
|
| Experimental: Domvanalimab + zimberelimab Q4W Combination Therapy Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab |
Drug: Domvanalimab
Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Other Names:
Drug: Zimberelimab
Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Other Names:
|
| Experimental: Domvanalimab and Zimberelimab Q6W combination therapy Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab |
Drug: Domvanalimab
Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Other Names:
Drug: Zimberelimab
Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Other Names:
|
| Experimental: Fixed dose Domvanalimab Q3W or Q4W and Zimberelimab Q3W, Q4W Varying Doses of domvanalimab in Combination With Varying Doses of zimberelimab |
Drug: Domvanalimab
Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Other Names:
Drug: Zimberelimab
Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0 [From First Dose Date to 100 Days After Last Dose]
Number of Participants Treated with domvanalimab or domvanalimab in Combination with zimberelimab with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0
Secondary Outcome Measures
- AB154 Peak Plasma Concentration (Cmax) [Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Peak Plasma Concentration (Cmax) of domvanalimab
- Zimberelimab Peak Plasma Concentration (Cmax) [Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Peak Plasma Concentration (Cmax) of zimberelimab
- Domvanalimab Time of Peak Concentration (Tmax) [Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Time of Peak Concentration (Tmax) of domvanalimab
- Zimberelimab Time of Peak Concentration (Tmax) [Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Time of Peak Concentration (Tmax) of zimberelimab
- Domvanalimab Area Under the Plasma Concentration Versus Time Curve (AUC) [Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Area Under the Plasma Concentration Versus Time Curve (AUC) of domvanalimab
- Zimberelimab Area Under the Plasma Concentration Versus Time Curve (AUC) [Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Area Under the Plasma Concentration Versus Time Curve (AUC) of zimberelimab
- Immunogenicity Indicators: Anti-Drug Antibodies (ADA) [Day 1, Day 15, Day 29, Day 43, Day 57, Day 85 and 30 Days After Last Dose, up to 52 weeks]
Number of Participants who Develop Antidrug Antibodies to AB154 and/or AB122
- Overall Response Rate [First Dose Date to Progression or Last Tumor Assessment, up to 1 year]
Number of Participants with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.1
- Duration of Response [Start Date of Response to First Progression/Death, up to 1 year]
Time at Which Response Criteria are Met for Complete Response or Partial Response (Whichever Occurs First) Until the First Date of Recurrence, Progression or Death per RECIST v1.1
- Disease Control Rate [First Dose Date to First Progression/Death, up to 1 year]
Number of Participants with Complete Response, Partial Response, or Stable Disease for Greater Than 6 Months per RECIST v1.1
- Progression Free Survival [First Dose Date to First Progression/Death, up to 1 year]
Number of Participants Without Disease Progression per RECIST v1.1
- Overall Survival [First Dose Date to Date of Death, up to 1 year]
Overall Survival Rate, Defined as Time Between First Dose Date and Date of Death
Other Outcome Measures
- Domvanalimab Receptor Occupancy [Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Receptor Occupancy May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples
- Domvanalimab Immunophenotyping [Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Immunophenotyping May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples
- Domvanalimab Gene Expression [Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Gene Expression May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples
- Domvanalimab Cytokines [Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Cytokines May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples.
- .Zimberelimab Receptor Occupancy [Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Receptor Occupancy May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples
- Zimberelimab Immunophenotyping [Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Immunophenotyping May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples
- Zimberelimab Cytokines [: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141 and 30 Days After Last Dose, up to 52 weeks]
Cytokines May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples
- Zimberelimab Gene Expression [Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141, and 30 Days After Last Dose, up to 52 weeks]
Gene Expression May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Capable of giving signed informed consent
-
Male or female participants ≥ 18 years of age at the time of screening
-
Negative serum pregnancy test at screening and prior to dosing on Cycle 1 Day 1; negative serum or urine pregnancy test on the first day of each subsequent treatment period
-
Participants with any pathologically confirmed solid tumor type for which no standard of care therapy exists
-
Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The measurable lesion must be outside of a radiation field if the participant received prior radiation
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
-
Confirmation that an archival tissue sample is available and ≤ 6 months old; if not, a new biopsy of a tumor must be obtained
-
Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed topical corticosteroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks (14 days) before investigational product administration. Physiologic doses of corticosteroids ≤ 10 mg/day of prednisone or its equivalent may be permitted
-
Prior surgery that required general anesthesia or other major surgery as defined by the Investigator must be completed at least 4 weeks before investigational product administration
-
Negative tests for hepatitis B surface antigen, hepatitis C virus antibody (or hepatitis C qualitative ribonucleic acid [RNA; qualitative]), and human immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening
-
Adequate organ and marrow function
Exclusion Criteria:
-
Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product
-
Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational product hazardous (eg, interstitial lung disease, active infections requiring antibiotics, recent hospitalization with unresolved symptoms)
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
-
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 100 days after the last dose of domvanalimab as monotherapy and in combination with zimberelimab.
-
Participants who require a Legally Authorized Representative (LAR) to provide informed consent on their behalf.
-
Any active autoimmune disease or a documented history of autoimmune disease or history of a syndrome that required systemic steroids or immunosuppressive medications, except for vitiligo or resolved childhood asthma/atopy. Participants with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study
-
Prior malignancy active within the previous year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
-
Has had prior chemotherapy, targeted small-molecule therapy, immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer), biologic agents or radiation therapy within 4 weeks (or 5 half-lives) prior to Day 1 or has not recovered from AEs due to a previously administered agent
-
Use of other investigational drugs within 28 days or at least 5 half-lives before investigational product administration.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The Angeles Clinic and Research Institute | Los Angeles | California | United States | 90025 |
| 2 | Carolina BioOncology Institute | Huntersville | North Carolina | United States | 28078 |
| 3 | MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
| 4 | START | San Antonio | Texas | United States | 78229 |
| 5 | Medical Oncology Associates, PS (dba Summit Cancer Centers) | Spokane | Washington | United States | 99208 |
| 6 | Albury, Australia | Albury | New South Wales | Australia | 2640 |
| 7 | Principal Investigator | Camperdown | New South Wales | Australia | 2050 |
| 8 | The Kinghorn Cancer Centre | Darlinghurst | New South Wales | Australia | 2010 |
| 9 | Scientia Clinical Research | Randwick | New South Wales | Australia | 2031 |
| 10 | Principal Investigator | Tweed Heads | New South Wales | Australia | 2480 |
| 11 | Principal Investigator | South Brisbane | Queensland | Australia | 4101 |
| 12 | Olivia Newton-John Cancer Research Institute | Heidelberg | Victoria | Australia | 3084 |
Sponsors and Collaborators
- Arcus Biosciences, Inc.
Investigators
- Study Director: Medical Director, Arcus Biosciences, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AB154CSP0001